{"product_id":"recombinant-human-serine-threonine-protein-kinase-lats1-lats1-partial-bhp10510991","title":"Recombinant Human Serine\/threonine-protein kinase LATS1 (LATS1), partial","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eRecombinant Human Serine\/threonine-protein kinase LATS1 (LATS1), partial is a recombinant protein reagent derived from Homo sapiens (Human) and produced in E.coli. It is commonly used to support Cancer research by enabling enzyme activity assays, kinetics\/structure–function studies and inhibitor or substrate screening in controlled in vitro settings.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eExpressed region:\u003c\/strong\u003e 705-1090aa. Region selection can focus on functional domains, improve solubility, or isolate interaction surfaces for targeted studies.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eExpression system:\u003c\/strong\u003e E.coli. Expression host can influence folding and the presence\/absence of post-translational modifications.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eTag \/ fusion:\u003c\/strong\u003e N-terminal 10xHis-tagged and C-terminal Myc-tagged. Tags can support purification and detection; evaluate potential tag effects when studying sensitive interactions.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eMolecular weight (reported):\u003c\/strong\u003e 49.4 kDa. Apparent size may vary with tags, processing, and gel conditions.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eWhen comparing results across batches or platforms, interpret signals in the context of construct design (region, tags) and expression host, especially for modification-dependent interactions.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eThe gene commonly associated with this target is \u003cstrong\u003eLATS1\u003c\/strong\u003e. LATS1 refers to a protein target that is studied across multiple biological contexts; annotations and nomenclature can vary by species and isoform. This product corresponds to the Homo sapiens (Human) sequence context, which can be important when comparing homologs or orthologs across model systems. For curated functional annotations, domains, and sequence features, consult primary databases (e.g., UniProt\/NCBI) and the recent literature for the specific organism and isoform.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e \u003cli\u003eMapping pathway dependencies and signaling networks that drive tumor growth and drug resistance.\u003c\/li\u003e \u003cli\u003eDeveloping and benchmarking biomarker assays (e.g., immunoassays or binding reagents) for candidate targets.\u003c\/li\u003e \u003cli\u003eCharacterizing protein variants, domains, or interaction partners relevant to targeted therapeutics and precision oncology.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003cstrong\u003eRelevance:\u003c\/strong\u003e Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3\/MST2 and STK4\/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1\/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1\/TAZ. Phosphorylation of YAP1 by LATS1 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in maintenance of ploidy through its actions in both mitotic progression and the G1 tetraploidy checkpoint. Negatively regulates G2\/M transition by down-regulating CDK1 kinase activity. Involved in the control of p53 expression. Affects cytokinesis by regulating actin polymerization through negative modulation of LIMK1. May also play a role in endocrine function. Plays a role in mammary gland epithelial cell differentiation, both through the Hippo signaling pathway and the intracellular estrogen receptor signaling pathway by promoting the degradation of ESR1.\u003c\/p\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e \u003cli\u003eEnzyme activity assays and kinetics measurements with defined substrates\/cofactors.\u003c\/li\u003e \u003cli\u003eInhibitor, activator, or substrate screening in biochemical assay formats.\u003c\/li\u003e \u003cli\u003eStructure–function analysis to interpret how sequence changes impact catalytic performance.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eIn quantitative assay development, changes in binding or activity readouts are typically interpreted relative to appropriate negative\/positive controls and, where possible, orthogonal assay formats that support the same conclusion.\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e \u003cli\u003eRecombinant constructs may represent a defined region (domain) rather than the full-length protein; interpret results in the context of the expressed region.\u003c\/li\u003e \u003cli\u003eTag or fusion elements can aid purification and detection but may influence binding surfaces or oligomerization; consider tag controls when relevant.\u003c\/li\u003e \u003cli\u003eSpecies and isoform differences can affect interaction partners and post-translational modifications; align experimental controls to the intended biological context.\u003c\/li\u003e \u003cli\u003eE. coli expression can limit eukaryotic post-translational modifications; for modification-dependent biology, interpret results accordingly.\u003c\/li\u003e \u003c\/ul\u003e \u003c!-- Sources (internal): - UniProtKB entry for O95835 — UniProt — https:\/\/www.uniprot.org\/uniprotkb\/O95835\/entry - NCBI Gene search (LATS1) — NCBI — https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=LATS1 - PubMed search (LATS1) — NCBI — https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=LATS1 - RCSB PDB search (LATS1) — RCSB PDB — https:\/\/www.rcsb.org\/search?query=LATS1 - Reactome Pathway Browser — Reactome — https:\/\/reactome.org\/ --\u003e","brand":"CUSABIO TECHNOLOGY LLC","offers":[{"title":"1 mg","offer_id":53065336422765,"sku":"CSB-EP012769HU-1MG","price":2466.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53065524478317,"sku":"CSB-EP012769HU-100UG","price":578.0,"currency_code":"USD","in_stock":true},{"title":"20 ug","offer_id":53065524511085,"sku":"CSB-EP012769HU-20UG","price":306.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/CSB-EP012769HU-SDS.jpg?v=1772476665","url":"https:\/\/www.ebiohippo.com\/products\/recombinant-human-serine-threonine-protein-kinase-lats1-lats1-partial-bhp10510991","provider":"BioHippo","version":"1.0","type":"link"}